The estimated Net Worth of Healthcare Sabaxter Interna... is at least $2.6 Million dollars as of 30 July 2013. Healthcare Interna owns over 330,000 units of Onconova Therapeutics Inc stock worth over $2,603,295 and over the last 11 years Healthcare sold ONTX stock worth over $0.
Healthcare has made over 1 trades of the Onconova Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Healthcare bought 330,000 units of ONTX stock worth $4,950,000 on 30 July 2013.
The largest trade Healthcare's ever made was buying 330,000 units of Onconova Therapeutics Inc stock on 30 July 2013 worth over $4,950,000. On average, Healthcare trades about 165,000 units every 0 days since 2013. As of 30 July 2013 Healthcare still owns at least 2,603,295 units of Onconova Therapeutics Inc stock.
You can see the complete history of Healthcare Interna stock trades at the bottom of the page.
Healthcare's mailing address filed with the SEC is THURGAUERSTRASSE 130ONE BAXTER PARKWAY, DF2-1W, , GLATTPARK (OPFIKON)DEERFIELD, V8IL, 815260015.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683, and Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: